BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33044014)

  • 1. Treatment of Oligometastatic Disease in Squamous Cell Carcinoma of the Head and Neck.
    Vincent AG; Wang W; Shokri T; Ducic Y
    Laryngoscope; 2021 May; 131(5):E1476-E1480. PubMed ID: 33044014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target delineation for postoperative treatment of head and neck cancer.
    Evans M; Beasley M
    Oral Oncol; 2018 Nov; 86():288-295. PubMed ID: 30409314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
    Daniels CP; Bressel M; Corry J; Cole A; Chua MS; Tiong A; Hirshoren N; Dixon B; McDowell L
    Pract Radiat Oncol; 2020; 10(1):29-35. PubMed ID: 31606546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
    Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
    JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.
    Amoils M; Lee CS; Sunwoo J; Aasi SZ; Hara W; Kim J; Sirjani D; Colevas AD; Chang AL; Divi V
    Head Neck; 2017 May; 39(5):881-885. PubMed ID: 28252823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
    Balk M; Rupp R; Mantsopoulos K; Allner M; Grundtner P; Mueller SK; Traxdorf M; Eckstein M; Speer S; Semrau S; Fietkau R; Iro H; Hecht M; Gostian AO
    BMC Cancer; 2021 Nov; 21(1):1236. PubMed ID: 34794411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma.
    Tang E; Lahmi L; Meillan N; Pietta G; Albert S; Maingon P
    Curr Oncol Rep; 2019 Nov; 21(11):102. PubMed ID: 31728650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection.
    Boros A; Blanchard P; Dade A; Gorphe P; Breuskin I; Even C; Nguyen F; Deutsch E; Bidault F; Janot F; Temam S; Mirghani H; Tao Y
    Laryngoscope; 2021 Mar; 131(3):E846-E850. PubMed ID: 32833260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated With the Choice of Radiation Therapy Treatment Facility in Head and Neck Cancer.
    Sullivan CB; Al-Qurayshi Z; Anderson CM; Seaman AT; Pagedar NA
    Laryngoscope; 2021 May; 131(5):1019-1025. PubMed ID: 32846018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
    Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
    JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
    Haring CT; Kana LA; Dermody SM; Brummel C; McHugh JB; Casper KA; Chinn SB; Malloy KM; Mierzwa M; Prince MEP; Rosko AJ; Shah J; Stucken CL; Shuman AG; Brenner JC; Spector ME; Worden FP; Swiecicki PL
    Cancer; 2023 Sep; 129(18):2817-2827. PubMed ID: 37162461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma.
    Nøhr A; Gram SB; Charabi B; Tvedskov JF; Wessel I; Friborg J; Håkansson K; von Buchwald C; Fischer BM; Rasmussen JH
    Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2895-2902. PubMed ID: 31297609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of bone metastases from head and neck squamous cell carcinoma.
    Suzuki A; Kashiwagi N; Doi H; Ishii K; Doi K; Kitano M; Kozuka T; Hyodo T; Tsurusaki M; Yagyu Y; Nakanishi K
    Auris Nasus Larynx; 2020 Apr; 47(2):262-267. PubMed ID: 31445714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
    Mroz EA; Patel KB; Rocco JW
    Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of primary surgery versus primary radiotherapy on unknown primary head and neck squamous cell carcinoma: a systematic review protocol.
    Dharmawardana N; Campbell JM; Carney AS; Boase S
    JBI Database System Rev Implement Rep; 2018 Feb; 16(2):308-315. PubMed ID: 29419616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
    Bonomo P; Greto D; Desideri I; Loi M; Di Cataldo V; Orlandi E; Iacovelli NA; Becherini C; Visani L; Salvestrini V; Mariotti M; Livi L
    Oral Oncol; 2019 Jun; 93():1-7. PubMed ID: 31109688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
    Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
    Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the multidisciplinary tumor board on head and neck cancer outcomes.
    Liu JC; Kaplon A; Blackman E; Miyamoto C; Savior D; Ragin C
    Laryngoscope; 2020 Apr; 130(4):946-950. PubMed ID: 31095740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
    Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
    Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.